Find policies, billing codes, payers, states, and providers
Visual Information Processing Evaluation and Orthoptic and Vision Therapy
Customize your policy alerts
Sign up for UnitedHealthcare Policy SRST2026T0072GG alerts
Get alerted when Policy SRST2026T0072GG changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage and evidence assessment for remote, online, digital, and in-office orthoptic/vision therapy interventions for amblyopia and related visual processing treatments, and informs benefit determination for UnitedHealthcare plans and providers.
Removed list of proven and medically necessary indications including occlusion therapy/pharmacologic penalization for amblyopia, orthoptic/vision therapy for convergence insufficiency, and prism adaptation therapy for esotropia.
Revised list of unproven and not medically necessary indications and removed several items including vision restoration therapy for post-stroke visual field deficits and visual information processing evaluation to diagnose learning disabilities.
Removed CPT codes 92065, 92066, and 92499 from Applicable Codes.
Updated Clinical Evidence and References and removed Description of Services section.
Coverage Criteria for Remote / Digital Amblyopia Therapies
Remote/online/digital therapies for amblyopia — stance
Policy summary and evidence synthesis
See Benefit Considerations; some UnitedHealthcare plans may expressly exclude vision therapy benefits.
Key limitations include small sample sizes, short follow-up, high dropout or low adherence in some trials, and variable study designs and devices.
Longer-term and larger comparative studies are needed to establish durable efficacy and equivalence or superiority to standard care.
Coverage with criteria (suggested)
Consider coverage when clinical criteria and evidence-aligned conditions are met:
AAO and specialty guidance recognize amblyopia as a condition warranting treatment.
AAO recommends refractive correction as the initial step and patching for moderate amblyopia.
AAO notes amblyopia treatment can be effective in older children/adolescents.
Prior-authorization expectations should include baseline and follow-up best-corrected VA and adherence data; RCTs used primary endpoints at 2–16 weeks or 12 weeks.
Some devices (e.g., CureSight, certain dichoptic therapeutics) have RCT data showing short-term benefit but require longer-term confirmation.
Not a full replacement for conventional therapy
Not supported as sole replacement when ALL of the following are present:
Systematic reviews found no consistent superiority of binocular therapy over patching and highlighted heterogeneity and inconsistency across trials.
Low adherence in RCTs was associated with reduced treatment effect and limits generalizability.
AAO guidance identifies refractive correction and patching as standard initial therapies.
Certain UnitedHealthcare plans exclude benefits for Vision Therapy (orthoptic training). Verify coverage by referring to the member-specific benefit plan document before providing or billing for vision therapy services.
Binocular or digital vision therapy should not be considered a proven, standalone replacement for conventional occlusion (patching) in all cases. A systematic review and meta-analysis found no significant difference in visual acuity or stereopsis between binocular treatment and patching and concluded binocular approaches cannot fully replace traditional patching; they may serve as complementary therapy in select cases.
Policy revision effective 04/01/2026 updated the Coverage Rationale. The revision removed the prior list of proven and medically necessary indications (including occlusion/pharmacologic penalization for amblyopia and orthoptic/vision therapy for convergence insufficiency) and revised the list of unproven and not medically necessary indications; see Policy History for the full list of removed items.
Remote, online, and digital therapies for amblyopia are considered unproven and not medically necessary due to insufficient evidence of efficacy. Randomized trials and systematic reviews report mixed results, heterogeneity across studies, and adherence limitations that prevent firm conclusions that these modalities provide consistent, clinically meaningful benefit compared with standard therapies.
Coverage decisions that consider digital or binocular vision therapy should require documentation of baseline refractive correction (e.g., evidence that best-corrected visual acuity was established) and objective plans for monitoring adherence and response. Trials frequently measured best-corrected visual acuity (logMAR or Snellen) and used objective device adherence data; absence of these elements limits interpretation of treatment effect.
The policy revision on 04/01/2026 also updated the unproven and not medically necessary indications. Refer to Policy History for details on items removed from the unproven/not medically necessary list, including certain vision restoration and visual information processing items.
Coding and Applicable Codes
| 0687T | Treatment of amblyopia using an online digital program; device supply, educational set-up, and initial session |
| 0688T | Treatment of amblyopia using an online digital program; assessment of patient performance and program data by physician or other qualified health care professional, with report, per calendar month |
| 0704T | Remote treatment of amblyopia using an eye tracking device; device supply with initial set-up and patient education on use of equipment |
| 0705T | Remote treatment of amblyopia using an eye tracking device; surveillance center technical support including data transmission with analysis, with a minimum of 18 training hours, each 30 days |
| 0706T | Remote treatment of amblyopia using an eye tracking device; interpretation and report by physician or other qualified health care professional, per calendar month |
| No codes listed |
| No codes listed |
| K221375 | CureSight FDA submission/clearance reference (Decision date 2022 Sep 29) |
| DEN210005 | Luminopia One De Novo classification |
| K012530 | RevitalVision 510(k) clearance |
Provider Actions, Prior Authorization, and Documentation
Prior Authorization & Coding Verification
Prior authorization or benefit verification may be required prior to coverage. The codes listed are for reference only and do not guarantee coverage; verify member-specific benefits and any plan exclusions. Services billed using codes removed from the policy or not covered by the member's plan may be administratively denied.
- Verify member-specific benefit plan and applicable state/federal mandates before providing services
- Prior authorization may be required when coverage is considered — submit documentation as indicated
- Listing of a code does not imply coverage or guarantee payment
Documentation Required When Coverage Is Considered
If coverage is being requested (for example, under a plan that does not exclude Vision Therapy), submit required clinical documentation to support medical necessity: baseline and follow-up best-corrected visual acuity (BCVA) measurements, stereoacuity when available, description of prior standard therapies tried (refractive correction, occlusion/patching, pharmacologic penalization), dates and duration of those therapies, treatment modality proposed, objective adherence data if available, and documented clinical response.
- Baseline and follow-up best-corrected visual acuity (BCVA) for amblyopic and fellow eye
- Stereoacuity measurements when available
- Description and dates of prior standard therapies tried (refractive correction, occlusion/patching, atropine penalization)
- Objective adherence data and clinical response during prior treatments
- Treatment plan specifying modality, frequency, duration, and monitoring plan
Standard Therapy Precedence
Conventional, guideline-based therapies remain the primary standard of care for amblyopia and should be used before considering remote/online/digital therapies. Refractive correction is the initial step; for moderate amblyopia, patching (typically 2 hours/day) or pharmacologic penalization (e.g., weekend atropine) is the recommended first-line treatment. Digital or remote vision therapies are considered unproven by this policy and do not replace standard treatments unless a member-specific benefit and clinical rationale support use.
- Initial therapy: full-time refractive correction (glasses) for eligible children
- First-line follow-up therapies: occlusion (patching) or pharmacologic penalization (atropine) per AAO guidance
- Digital/remote therapies should not supplant standard care; consider only after standard therapies have been applied and documented or per member benefit provisions
Denial Risk and Documentation Shortfalls
Remote, online, and/or digital therapies for amblyopia are considered unproven and not medically necessary when the member's plan excludes Vision Therapy; denials may be issued for lack of sufficient independent evidence or for poor adherence leading to lack of demonstrated benefit. Short follow-up durations, absence of objective adherence monitoring, or missing documentation of prior standard therapies are common triggers for additional information requests or denial.
- Denial triggers include: member plan exclusion for Vision Therapy, insufficient clinical evidence, inadequate follow-up, missing documentation of prior standard therapies, or lack of objective adherence data
- Requests for additional documentation may be made when follow-up is short or safety data are limited
- Use independent clinical judgment and reference member-specific benefits when determining whether to request prior authorization
Background and Scope
Amblyopia is decreased vision that arises from abnormal visual development in infancy and childhood and typically affects one eye more than the other. Standard, evidence-based treatments include refractive correction (the initial step) and, when indicated, occlusion therapy (patching) or pharmacologic penalization (e.g., atropine) to stimulate the amblyopic eye. Vision Therapy (VT) is an active program of supervised in-office and at-home exercises with adjunctive tools intended to improve binocular function and visual skills, but VT modalities vary and the evidence for digital or remote VT as a replacement for standard care is currently limited.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.